{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T08:45:45Z","timestamp":1765356345290},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T00:00:00Z","timestamp":1521676800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11606-017-4279-4","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T15:26:57Z","timestamp":1521732417000},"page":"847-854","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project"],"prefix":"10.1007","volume":"33","author":[{"given":"Jos\u00e9 Miguel","family":"Rivera-Caravaca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Rold\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Romera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Asunci\u00f3n","family":"Esteve-Pastor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicente","family":"Vicente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Mar\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,22]]},"reference":[{"key":"4279_CR1","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3109\/07853890.2010.507601","volume":"42","author":"A Lopez-Cuenca","year":"2010","unstructured":"Lopez-Cuenca A, Marin F, Roldan V, Gonzalez-Conejero R, Hernandez-Romero D, Valdes M, et al. Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. Ann Med. 2010;42:562\u201375.","journal-title":"Ann Med"},{"key":"4279_CR2","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","volume":"373","author":"T Watson","year":"2009","unstructured":"Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow\u2019s triad revisited. Lancet. 2009;373:155\u201366.","journal-title":"Lancet"},{"key":"4279_CR3","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1093\/eurheartj\/ehw119","volume":"38","author":"HM Spronk","year":"2017","unstructured":"Spronk HM, De Jong AM, Verheule S, De Boer HC, Maass AH, Lau DH, et al. Hypercoagulability causes atrial fibrosis and promotes atrial fibrillation. Eur Heart J. 2017;38:38\u201350.","journal-title":"Eur Heart J"},{"key":"4279_CR4","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1055\/s-0038-1650247","volume":"75","author":"R Mitusch","year":"1996","unstructured":"Mitusch R, Siemens HJ, Garbe M, Wagner T, Sheikhzadeh A, Diederich KW. Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost. 1996;75:219\u201323.","journal-title":"Thromb Haemost"},{"key":"4279_CR5","first-page":"673","volume":"157","author":"SR Kahn","year":"1997","unstructured":"Kahn SR, Solymoss S, Flegel KM. Nonvalvular atrial fibrillation: evidence for a prothrombotic state. CMAJ. 1997;157:673\u201381.","journal-title":"CMAJ"},{"key":"4279_CR6","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1161\/01.STR.27.10.1760","volume":"27","author":"HJ Lin","year":"1996","unstructured":"Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996;27:1760\u20134.","journal-title":"Stroke"},{"key":"4279_CR7","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"4279_CR8","doi-asserted-by":"crossref","unstructured":"Violi F, Soliman EZ, Pignatelli P, Pastori D. Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. J Am Heart Assoc. 2016;5.","DOI":"10.1161\/JAHA.116.003347"},{"key":"4279_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s11739-010-0352-2","volume":"5","author":"L Polimeni","year":"2010","unstructured":"Polimeni L, Perri L, Saliola M, Basili S, Violi F. The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue. Intern Emerg Med. 2010;5:91\u20134.","journal-title":"Intern Emerg Med"},{"key":"4279_CR10","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ahj.2008.06.029","volume":"156","author":"S Goto","year":"2008","unstructured":"Goto S, Bhatt DL, Rother J, Alberts M, Hill MD, Ikeda Y, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J. 2008;156:855\u201363, 863.e852.","journal-title":"Am Heart J"},{"key":"4279_CR11","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.amjmed.2016.06.045","volume":"129","author":"L Fauchier","year":"2016","unstructured":"Fauchier L, Villejoubert O, Clementy N, Bernard A, Pierre B, Angoulvant D, et al. Causes of deaths and influencing factors in patients with atrial fibrillation. Am J Med. 2016;129:1278\u201387.","journal-title":"Am J Med"},{"key":"4279_CR12","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/1076029615615959","volume":"23","author":"N Singh","year":"2017","unstructured":"Singh N, Pati HP, Tyagi S, Upadhyay AD, Saxena R. Evaluation of the Diagnostic Performance of Fibrin Monomer in Comparison to d-Dimer in Patients With Overt and Nonovert Disseminated Intravascular Coagulation. Clin Appl Thromb Hemost. 2017;23:460\u20135.","journal-title":"Clin Appl Thromb Hemost"},{"key":"4279_CR13","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s11239-012-0721-y","volume":"34","author":"H Hou","year":"2012","unstructured":"Hou H, Ge Z, Ying P, Dai J, Shi D, Xu Z, et al. Biomarkers of deep venous thrombosis. J Thromb Thrombolysis. 2012;34:335\u201346.","journal-title":"J Thromb Thrombolysis"},{"key":"4279_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest. 2010;137:263\u201372.","journal-title":"Chest"},{"key":"4279_CR15","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093\u20131100.","journal-title":"Chest"},{"key":"4279_CR16","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837\u201345.","journal-title":"Biometrics"},{"key":"4279_CR17","doi-asserted-by":"crossref","unstructured":"Pencina MJ, D\u2019Agostino RB Sr, D\u2019Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157\u201372; discussion 207\u201312.","DOI":"10.1002\/sim.2929"},{"key":"4279_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1472-6947-8-53","volume":"8","author":"AJ Vickers","year":"2008","unstructured":"Vickers AJ, Cronin AM, Elkin EB, Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak. 2008;8:53.","journal-title":"BMC Med Inform Decis Mak"},{"key":"4279_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1177\/0272989X06295361","volume":"26","author":"AJ Vickers","year":"2006","unstructured":"Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Mak. 2006;26:565\u201374.","journal-title":"Med Decis Mak"},{"key":"4279_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1161\/CIRCRESAHA.116.309955","volume":"120","author":"MR Thomas","year":"2017","unstructured":"Thomas MR, Lip GY. Novel Risk Markers and Risk Assessments for Cardiovascular Disease. Circ Res. 2017;120:133\u201349.","journal-title":"Circ Res"},{"key":"4279_CR21","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.1016\/j.jacc.2012.11.082","volume":"61","author":"Z Hijazi","year":"2013","unstructured":"Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013;61:2274\u201384.","journal-title":"J Am Coll Cardiol"},{"key":"4279_CR22","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1161\/CIRCULATIONAHA.111.038729","volume":"125","author":"Z Hijazi","year":"2012","unstructured":"Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125:1605\u201316.","journal-title":"Circulation"},{"key":"4279_CR23","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1001\/jamacardio.2016.3311","volume":"1","author":"CT Ruff","year":"2016","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Murphy SA, Brown K, Jarolim P, et al. Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation: A Subanalysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial. JAMA Cardiol. 2016;1:999\u20131006.","journal-title":"JAMA Cardiol"},{"key":"4279_CR24","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3109\/07853890.2014.912835","volume":"46","author":"E Danese","year":"2014","unstructured":"Danese E, Montagnana M, Cervellin G, Lippi G. Hypercoagulability, D-dimer and atrial fibrillation: an overview of biological and clinical evidence. Ann Med. 2014;46:364\u201371.","journal-title":"Ann Med"},{"key":"4279_CR25","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1160\/TH16-08-0658","volume":"116","author":"B Freedman","year":"2016","unstructured":"Freedman B, Lip GY. \u201cUnreal world\u201d or \u201creal world\u201d data in oral anticoagulant treatment of atrial fibrillation. Thromb Haemost. 2016;116:587\u20139.","journal-title":"Thromb Haemost"},{"key":"4279_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.006490","volume":"6","author":"JM Rivera-Caravaca","year":"2017","unstructured":"Rivera-Caravaca JM, Rold\u00e1n V, Esteve-Pastor MA, Vald\u00e9s M, Vicente V, Lip GYH, et al. Long-Term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC-Stroke and CHA2DS2-VASc Scores. J Am Heart Assoc. 2017;6:e006490.","journal-title":"J Am Heart Assoc"},{"key":"4279_CR27","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1160\/TH17-10-0710","volume":"117","author":"MA Esteve-Pastor","year":"2017","unstructured":"Esteve-Pastor MA, Rivera-Caravaca JM, Roldan V, Vicente V, Valdes M, Marin F, et al. Long-term bleeding risk prediction in \u2018real world\u2019 patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. The Murcia Atrial Fibrillation Project. Thromb Haemost. 2017;117:1848\u201358.","journal-title":"Thromb Haemost"},{"key":"4279_CR28","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1161\/01.ATV.17.4.628","volume":"17","author":"LV Lee","year":"1997","unstructured":"Lee LV, Ewald GA, McKenzie CR, Eisenberg PR. The relationship of soluble fibrin and cross-linked fibrin degradation products to the clinical course of myocardial infarction. Arterioscler Thromb Vasc Biol. 1997;17:628\u201333.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4279_CR29","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.amjcard.2004.07.144","volume":"94","author":"M Saigo","year":"2004","unstructured":"Saigo M, Waters DD, Abe S, Biro S, Minagoe S, Maruyama I, et al. Soluble fibrin, C-reactive protein, fibrinogen, factor VII, antithrombin, proteins C and S, tissue factor, D-dimer, and prothrombin fragment 1 + 2 in men with acute myocardial infarction <\/=45 years of age. Am J Cardiol. 2004;94:1410\u20133.","journal-title":"Am J Cardiol"},{"key":"4279_CR30","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/MBC.0b013e32832e0605","volume":"20","author":"V Dopsaj","year":"2009","unstructured":"Dopsaj V, Bogavac-Stanojevic N, Vasic D, Vukosavljevic D, Martinovic J, Kotur-Stevuljevic J, et al. Excluding deep venous thrombosis in symptomatic outpatients: is fibrin monomer aid to D-dimer analysis? Blood Coagul Fibrinolysis. 2009;20:546\u201351.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"4279_CR31","doi-asserted-by":"publisher","first-page":"3678017","DOI":"10.1155\/2017\/3678017","volume":"2017","author":"NK Toth","year":"2017","unstructured":"Toth NK, Csanadi Z, Hajas O, Kiss A, Nagy-Balo E, Kovacs KB, et al. Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation. Biomed Res Int. 2017;2017:3678017.","journal-title":"Biomed Res Int"},{"key":"4279_CR32","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.ijcard.2013.01.259","volume":"168","author":"T Sadanaga","year":"2013","unstructured":"Sadanaga T, Mitamura H. Soluble fibrin monomer complex levels during oral anticoagulant therapy do not predict subsequent thromboembolic events in patients with permanent atrial fibrillation. Int J Cardiol. 2013;168:578\u201380.","journal-title":"Int J Cardiol"},{"key":"4279_CR33","doi-asserted-by":"publisher","first-page":"41565","DOI":"10.1038\/srep41565","volume":"7","author":"A Garc\u00eda-Fern\u00e1ndez","year":"2017","unstructured":"Garc\u00eda-Fern\u00e1ndez A, Rold\u00e1n V, Rivera-Caravaca JM, Hern\u00e1ndez-Romero D, Vald\u00e9s M, Vicente V, et al. Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation? Sci Rep. 2017;7:41565.","journal-title":"Sci Rep"},{"key":"4279_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11739-015-1326-1","volume":"11","author":"D Pastori","year":"2016","unstructured":"Pastori D, Farcomeni A, Poli D, Antonucci E, Angelico F, Del Ben M, et al. Cardiovascular risk stratification in patients with non-valvular atrial fibrillation: the 2MACE score. Intern Emerg Med. 2016;11:199\u2013204.","journal-title":"Intern Emerg Med"},{"key":"4279_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/jamainternmed.2013.11912","volume":"174","author":"EZ Soliman","year":"2014","unstructured":"Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA, et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174:107\u201314.","journal-title":"JAMA Intern Med"}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11606-017-4279-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-017-4279-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-017-4279-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,13]],"date-time":"2019-10-13T08:10:39Z","timestamp":1570954239000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11606-017-4279-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,22]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["4279"],"URL":"https:\/\/doi.org\/10.1007\/s11606-017-4279-4","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,22]]},"assertion":[{"value":"8 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"GYHL is a consultant for Bayer\/Janssen, BMS\/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo; and a speaker for Bayer, BMS\/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo. No fees are received personally.All remaining authors declare that they do not have a conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}